Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Daiichi Sankyo
US Department of Justice
Accenture
Boehringer Ingelheim
Fish and Richardson
Chubb
Queensland Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OCTREOTIDE ACETATE

« Back to Dashboard

Clinical Trials for Octreotide Acetate

Trial ID Title Status Sponsor Phase Summary
NCT00003057 Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed Cancer and Leukemia Group B Phase 3 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed Southwest Oncology Group Phase 3 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
NCT00003057 Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer Completed Eastern Cooperative Oncology Group Phase 3 RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Octreotide Acetate

Condition Name

Condition Name for Octreotide Acetate
Intervention Trials
Acromegaly 9
Diabetic Retinopathy 4
Islet Cell Tumor 2
Diarrhea 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Octreotide Acetate
Intervention Trials
Acromegaly 9
Carcinoid Tumor 5
Neuroendocrine Tumors 5
Retinal Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Octreotide Acetate

Trials by Country

Trials by Country for Octreotide Acetate
Location Trials
United States 172
Canada 5
Romania 3
Ukraine 3
Hungary 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Octreotide Acetate
Location Trials
California 7
New Jersey 6
Ohio 6
Tennessee 5
Minnesota 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Octreotide Acetate

Clinical Trial Phase

Clinical Trial Phase for Octreotide Acetate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 12
Phase 2 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Octreotide Acetate
Clinical Trial Phase Trials
Completed 18
Terminated 6
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Octreotide Acetate

Sponsor Name

Sponsor Name for Octreotide Acetate
Sponsor Trials
National Cancer Institute (NCI) 10
Novartis Pharmaceuticals 6
Novartis 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Octreotide Acetate
Sponsor Trials
Industry 19
Other 10
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Farmers Insurance
Accenture
Teva
AstraZeneca
Baxter
Cipla
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.